Active Biotech Ab

Pharmacia Ab

Other

Kabi Pharmacia Ab

Anders K Bjork

Gunnar Hedlund

Erik G Christensson

Tomas Fex

Stig Jonsson

Aina L Abramo

Gunnar Andersson

Erik Christensson

Karl Erik Jansson

Knut G Olsson

Tomas Fristedt

Goran Pettersson

Curt Nordvi

Lisbeth Abramo

Elisabeth Seifert

Arne Nilsson

Tomas Leanderson

Torbjorn Lundstedt

Bengt K Gustafsson

Catarina Ludwig

Jin Chang Wu

A stable solid pharmaceutical composition consisting essentially of an effective amount of a crystalline salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; andat least one pharmaceutical excipient;said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.

Crystalline salts of quinoline compounds and methods for preparing them

Immune enhancement

The invention is related to compounds of general formula (I) wherein R is methyl, ethyl, n-propyl, iso-propyl, n-butyl or allyl; R' is methyl, methoxy, fluoro, chloro, bromo, trifluoromethyl, or OCH.sub.x F.sub.y, wherein

Quinoline derivatives

The invention is related to compounds of general formula (I) ##STR1## wherein R is Me, Et, n-Pr, iso-Pr, n-Bu, iso-Bu, sec.-Bu or allyl; R' is hydrogen, Me, MeO, fluoro, chloro, brorno, CF.sub.3, or OCH.sub.x F.sub.y ; R' is hydrogen or fluoro, with the proviso that R' is fluoro when R' is fluoro; and further when R' and R' are both hydrogen, R is not Me; R.sub.4 is selected from hydrogen and pharmaceutically acceptable inorganic and organic cations; R.sub.5 is selected from MeS, EtS, n-PrS, iso-PrS, MeSO, EtSO, MeSO.sub.2 and EtSO.sub.2 ; wherein x=0-2, y=1-3 with the proviso that x+y=3; and Me is methyl, Et is ethyl, Pr is propsy and Bu is butyl; and any tautomer, optical isomer and racemate thereof. The invention also relates to pharmaceutical compositions containing a compound of the general formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of the compounds of formula (I), as well as methods for the treatment of mammals suffering from diseases resulting from autoimmunity and pathological inflammation by administering of a compound having the formula (I) to said mammal.

The invention relates to compounds of general formula (I) ##STR1## wherein R is selected from ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec.-butyl and allyl; R.sub.4 is selected from hydrogen and pharmaceutically acceptable inorganic and organic cations; R.sub.5 is selected from methyl, ethyl, n-propyl, iso-propyl, methoxy, ethoxy, chloro, bromo, CF.sub.3, and OCH.sub.x F.sub.y ; wherein x=0-2, y=1-3 with the proviso that x+y=3; R.sub.6 is hydrogen; or R.sub.5 and R.sub.6 taken together are methylenedioxy; and any tautomer hereof. The invention also relates to pharmaceutical compositions containing a compound of the general formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of the compounds of formula (I), as well as methods of treating mammals suffering from diseases resulting from autoimmunity and pathological inflammation by administering a compound having the formula (I) to said mammal.

Nicotinic acid esters

The present invention relates to the relief or prevention of withdrawal syndrome resulting from addiction to non-opiate type drugs of abuse and/or the suppression of dependence on non-opiate type drugs of abuse by administering to a person in need thereof, an effective amount of certain diphenylbutyl-piperazine-carboxamides including 4-[4,4-bis(4-fluorophenyl)butyl]-N-ethyl-1-piperazine-carboxamide which is known as amperozide.

Use of diphenylbutyl-piperazinecarboxamides in the treatment of

Method for treating substance abuse disorders

The present invention relates to a method for treating a patient suffering from therapy-resistant schizophrenia by administering to the patient a therapeutically effective amount of amperozide.

Method of treating therapy-resistant schizophrenia with amperozide

A series of 1-piperazinecarboxamide derivatives of the following formula: ##STR1## The compounds of the present invention are neuropharmacological agents intended for the treatment of mental disorders, such as psychoses and depression.

Novel 1-piperazinecarboxamide derivatives

1-piperazinocarboxylates and pharmaceutical compositions containing them

Diphenylbutyl-1-acylpiperazines

Growing community of inventors

Jagarevagen, Sweden

Anders K Bjork